The efficacy of a HH pathway inhibitor, glasdegib, which targets a smoothened protein (SMO), a G protein-coupled receptor interacting with PTCH1, was evaluated by Cortes et al. in AML and high-risk MDS patients who were not eligible for intensive chemotherapy [81]. The gene discussed is SMO; the disease is myelodysplastic syndrome.